Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Go back to Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 196.58 -2.09 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $198.67 | 52 Week High | $333.65 | |||
| Open | $200.22 | 52 Week Low | $223.02 | |||
| Day High | $200.99 | P/E | 25.17 | |||
| Day Low | $193.20 | EPS | $7.81 | |||
| Volume | 1,729,827 | |||||
